JP2023514611A - タンパク質ベースの精製マトリックス及びその使用方法 - Google Patents

タンパク質ベースの精製マトリックス及びその使用方法 Download PDF

Info

Publication number
JP2023514611A
JP2023514611A JP2022549696A JP2022549696A JP2023514611A JP 2023514611 A JP2023514611 A JP 2023514611A JP 2022549696 A JP2022549696 A JP 2022549696A JP 2022549696 A JP2022549696 A JP 2022549696A JP 2023514611 A JP2023514611 A JP 2023514611A
Authority
JP
Japan
Prior art keywords
seq
biologic
amino acid
matrix
purification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549696A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514611A5 (cg-RX-API-DMAC10.html
Inventor
エム. ルジンブール,ケリー
ズリッキー,マイケル
Original Assignee
アイソレア バイオ,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイソレア バイオ,インコーポレイテッド filed Critical アイソレア バイオ,インコーポレイテッド
Publication of JP2023514611A publication Critical patent/JP2023514611A/ja
Publication of JP2023514611A5 publication Critical patent/JP2023514611A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
JP2022549696A 2020-02-19 2021-02-19 タンパク質ベースの精製マトリックス及びその使用方法 Pending JP2023514611A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062978615P 2020-02-19 2020-02-19
US62/978,615 2020-02-19
PCT/US2021/018805 WO2021168270A1 (en) 2020-02-19 2021-02-19 Protein-based purification matrices and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026069454A Division JP2026129776A (ja) 2020-02-19 2026-04-20 タンパク質ベースの精製マトリックス及びその使用方法

Publications (2)

Publication Number Publication Date
JP2023514611A true JP2023514611A (ja) 2023-04-06
JP2023514611A5 JP2023514611A5 (cg-RX-API-DMAC10.html) 2024-03-18

Family

ID=77391793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549696A Pending JP2023514611A (ja) 2020-02-19 2021-02-19 タンパク質ベースの精製マトリックス及びその使用方法

Country Status (5)

Country Link
US (2) US20230099707A1 (cg-RX-API-DMAC10.html)
EP (1) EP4107167A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023514611A (cg-RX-API-DMAC10.html)
AU (1) AU2021222032A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021168270A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12269847B2 (en) 2018-08-16 2025-04-08 Donaldson Company, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
EP4107167A4 (en) * 2020-02-19 2024-04-03 Donaldson Company, Inc. PROTEIN-BASED PURIFICATION MATRIX AND METHODS OF USE
US12692483B2 (en) 2020-02-19 2026-07-28 Donaldson Company, Inc. Protein-based purification matrices and methods of using the same
EP4107268A4 (en) 2020-02-19 2024-03-27 Donaldson Company, Inc. PURIFICATION MATRICES COMPRISING VAA-BINDING POLYPEPTIDES AND METHODS OF USE THEREOF
AU2023307957A1 (en) * 2022-07-12 2025-01-09 Donaldson Company, Inc. Compositions and methods for improving viral transduction
WO2024110444A1 (en) 2022-11-21 2024-05-30 Chreto Aps Method for purification of a target product using affinity purification technology
EP4630444A1 (en) * 2022-12-08 2025-10-15 CSL Behring LLC Dissociable envelope binding proteins and uses thereof
WO2024169990A1 (zh) * 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
EP4467563A1 (en) * 2023-05-23 2024-11-27 JLP Health GmbH Ldlr derived polypeptides for anti-viral uses
WO2024240848A1 (en) * 2023-05-23 2024-11-28 Jlp Health Gmbh Ldlr derived polypeptides for anti-viral uses
JP2026524710A (ja) 2023-07-18 2026-07-23 ヴィヴェビオテック、ソシエダッド、リミターダ 精製樹脂およびその使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
JP2020534007A (ja) * 2017-09-22 2020-11-26 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 変異型ウイルスタンパク質

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
WO2000056774A1 (en) 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
WO2006110292A2 (en) * 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
CN101578373A (zh) * 2006-09-06 2009-11-11 费斯生物制药公司 融合肽治疗组合物
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
US20140088019A1 (en) * 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
EP2668962B1 (en) * 2012-05-29 2016-10-26 Albert-Ludwigs-Universität Freiburg Protein assembler
US20150218280A1 (en) * 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US9616138B1 (en) * 2013-09-26 2017-04-11 University Of South Florida Cargo carrying nanoparticles
KR20160067219A (ko) * 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CN104725515B (zh) * 2015-03-20 2017-11-14 扬州大学 一种类弹性蛋白多肽与柯萨奇腺病毒受体融合蛋白及其制备方法和应用
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
CN105175554B (zh) 2015-10-26 2018-09-25 扬州大学 一种类弹性蛋白多肽与热应激蛋白90α融合蛋白及其制备方法和应用
US10633662B2 (en) 2015-11-10 2020-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating AAV infection
US11149060B2 (en) * 2016-02-19 2021-10-19 University Of Delaware Functionalized nanoparticles for enhanced affinity precipitation of proteins
KR20190064600A (ko) * 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11464867B2 (en) 2018-02-13 2022-10-11 University Of Southern California Multimeric elastin-like polypeptides
CA3098565A1 (en) * 2018-04-29 2019-11-07 Claire G. ZHANG Scalable clarification process for recombinant aav production
US20220402995A1 (en) 2019-11-25 2022-12-22 Tosoh Corporation Improved adeno-associated virus-binding protein, method for producing same, and adeno-associated virus adsorbent using same
EP4107167A4 (en) * 2020-02-19 2024-04-03 Donaldson Company, Inc. PROTEIN-BASED PURIFICATION MATRIX AND METHODS OF USE
US12692483B2 (en) * 2020-02-19 2026-07-28 Donaldson Company, Inc. Protein-based purification matrices and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020534007A (ja) * 2017-09-22 2020-11-26 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 変異型ウイルスタンパク質
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACTA MICROBIOLOGICA SINICA, vol. 61, JPN6025010608, 2021, pages 621 - 630, ISSN: 0005550697 *
ARCH. VIROL., vol. 161, JPN6025010607, 2016, pages 279 - 287, ISSN: 0005550696 *
BIOCHEMISTRY, vol. 34, JPN6025010606, 1995, pages 14474 - 14481, ISSN: 0005758127 *
NAT. COMMUN., vol. Vol. 9:1029, JPN6025052210, 2018, pages 1 - 12, ISSN: 0005914447 *
PROC. NATL. ACAD. SCI. USA, vol. 110, no. 18, JPN6025010604, 2013, pages 7306 - 7311, ISSN: 0005758125 *
PROC. NATL. ACAD. SCI. USA, vol. 96, no. 22, JPN6025010605, 1999, pages 12766 - 12771, ISSN: 0005758126 *

Also Published As

Publication number Publication date
EP4107167A1 (en) 2022-12-28
EP4107167A4 (en) 2024-04-03
US11591576B2 (en) 2023-02-28
US20220010288A1 (en) 2022-01-13
US20230099707A1 (en) 2023-03-30
AU2021222032A1 (en) 2022-09-15
AU2021222032A9 (en) 2023-06-29
WO2021168270A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US11591576B2 (en) Protein-based purification matrices and methods of using the same
US20230340426A1 (en) Protein-based purification matrices and methods of using the same
JP2023515469A (ja) Aav結合ポリペプチドを含む精製マトリックス及びその使用方法
McNamara et al. Modern techniques for the isolation of extracellular vesicles and viruses
US12173307B2 (en) Methods for the purification of viral vectors
JP2023514611A5 (cg-RX-API-DMAC10.html)
US20240390517A1 (en) Aav8 capsid variants with enhanced liver targeting
WO2018089192A1 (en) Methods for isolating and purifying adeno-associated virus particles using salt
JP2025510977A (ja) エンベロープ型ウイルスを精製する方法
Gashti et al. Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate
WO2024121798A1 (en) Dissociable envelope binding proteins and uses thereof
Ghosh Developing downstream bioprocessing for gene and cell therapy applications
RU2853929C1 (ru) Способы удаления свободного фактора viii из препаратов лентивирусных векторов, модифицированных для экспрессии указанного белка
US20250382336A1 (en) Functionalized ubx protein materials for enhanced purification of antibodies
TW202417469A (zh) 純化供用於疫苗組成物之具有疏水性膜結構域的病毒蛋白的下游程序
Bakhshizadeh-Gashti Purification strategy development for the recombinant vesicular stomatitis virus (rVSV) based HIV vaccine
WO2026033062A1 (en) Purification of bionanoparticles
CN121794390A (zh) 纯化用树脂及其使用方法
Labisch et al. Lab-Scale Tools for Advanced LV Downstream Processing
Affinity et al. Tagging Retrovirus Vectors with a Metal

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420